Menopause is one of the biggest hormonal shifts the body goes through, and for many women it arrives with almost no preparation. The language is unclear, the timeline is longer than most people expect, and the treatment options go far beyond the HRT-or-nothing framing that still shows up in a lot of conversations. This guide walks through what perimenopause, menopause and postmenopause actually mean, what the common symptoms look like, and the UK pathway a clinician follows to help you decide what — if anything — to treat.
Perimenopause, menopause and postmenopause
Perimenopause is the transition phase. The ovaries start to run down, hormone levels fluctuate rather than fall smoothly, and periods become less predictable. It commonly starts in the mid-40s but can begin earlier or later. It typically lasts 4 to 8 years — sometimes longer. Symptoms often show up here before periods change much, which is why women can spend years wondering what's going on.
Menopause is a single point in time, defined retrospectively as 12 consecutive months without a period. The average age in the UK is 51. Menopause before 45 is called early menopause; before 40 is called premature ovarian insufficiency and warrants specialist involvement.
Postmenopause is the time from the menopause point onwards. Oestrogen stays low, and the health considerations shift toward bone density, cardiovascular risk and genitourinary symptoms, which can appear or worsen years after the last period.
The hormonal picture
Two ovarian hormones dominate the story: oestrogen and progesterone. Both fluctuate in perimenopause and then fall. Follicle-stimulating hormone (FSH) rises as the brain tries to stimulate ovaries that are becoming less responsive. Testosterone declines gradually with age, independently of menopause.
These changes affect systems well beyond reproduction. Oestrogen has receptors in the brain, blood vessels, bone, skin, bladder, vaginal tissue and joints. When it falls, downstream effects show up in temperature regulation, sleep, mood, cognition, skin, urinary symptoms, joint comfort and bone turnover — which is why the symptom list is so long and so variable.
The symptoms and how they're recognised
Menopausal symptoms fall into a few groups:
- Vasomotor symptoms — hot flushes and night sweats. Around three in four women experience these; for many they are severe enough to disrupt sleep or work.
- Sleep disturbance — often driven by night sweats but sometimes independent.
- Mood changes — low mood, anxiety, irritability, and for some women the return of PMS-like patterns before periods stop.
- Cognitive symptoms — brain fog, word-finding difficulty, poor concentration.
- Genitourinary syndrome of menopause — vaginal dryness, painful sex, urinary urgency, recurrent UTIs and thrush.
- Musculoskeletal symptoms — joint aches, stiffness and new-onset frozen shoulder are commonly hormone-related.
In the UK, NICE NG23 is the reference clinicians use. It advises that in women over 45 with typical symptoms and menstrual changes, menopause is diagnosed clinically — no blood test is needed. Blood tests (FSH) are usually only considered in women under 45, or where the picture is unclear. This surprises women who expect a lab confirmation but is deliberate: FSH fluctuates so much in perimenopause that a single result rarely helps.
Lifestyle and behavioural options
Before or alongside any medication, lifestyle measures are worth taking seriously. Regular exercise — including resistance training for bone health — helps with sleep, mood, weight and vasomotor symptoms. Reducing alcohol and caffeine, particularly in the evening, often reduces hot flushes and improves sleep. Layered clothing and cooler sleeping environments help with night sweats.
Cognitive behavioural therapy (CBT) has a genuine evidence base for vasomotor symptoms, sleep and mood in menopause. NICE NG23 lists it as an option to offer alongside or instead of medication. Access varies — some women self-refer through NHS Talking Therapies; others use private CBT.
Non-hormonal medication options
For women who can't or don't want HRT, there are non-hormonal medicines with useful evidence in menopause.
SSRIs and SNRIs — used off-label — can reduce the frequency and severity of hot flushes. Examples include venlafaxine, paroxetine and citalopram. The effect on vasomotor symptoms is separate from any effect on mood. Response is usually assessed after 4 to 8 weeks.
Clonidine — an older centrally-acting agent — is licensed for menopausal flushing and can be a useful option when SSRIs are not appropriate. Side effects (dry mouth, low blood pressure, sedation) limit some women.
Vaginal moisturisers and lubricants address genitourinary symptoms without hormones. For persistent local symptoms, low-dose vaginal oestrogen has very little systemic absorption and can be used in most women, including some who cannot use systemic HRT.
Newer non-hormonal options for vasomotor symptoms — including neurokinin-3 receptor antagonists — are now available in UK practice, and a clinician can advise whether they're appropriate. Your clinician will advise based on your individual circumstances.
Where HRT fits
For women with troublesome menopausal symptoms and no specific reason to avoid it, HRT is usually the most effective single treatment. It reliably reduces vasomotor symptoms, helps sleep, often lifts mood, and protects bone density while it's being taken. It comes as tablets, patches, gels and sprays, and is combined with a progestogen for women who still have a uterus.
The decision to start HRT is individualised — a clinician balances symptom severity against personal risk factors (breast history, clot risk, migraine, cardiovascular risk). Route matters: transdermal oestrogen does not carry the small clot risk seen with oral oestrogen. If HRT is right for you, the first review is usually at around three months, then annually.
For a fuller walk-through of what HRT is, the components and the regimens, see our companion article HRT explained — what it is and who it's for. If you want the timeline for symptoms once treatment starts, our piece on how long HRT takes to work covers it.
From GP to specialist — the pathway
Most menopause care in the UK is delivered in primary care by a GP or a suitably trained clinician (nurse prescriber, pharmacist prescriber, or menopause-trained GP). A typical pathway looks like:
- Initial consultation — history of symptoms, menstrual pattern, medical history, family history, and a discussion of options. Diagnosis is usually clinical.
- Trial of treatment — this might be a lifestyle plan, CBT referral, a non-hormonal medicine, an HRT regimen, or a combination. A first review is booked, usually at 3 months.
- Review and adjust — dose, route or regimen changes are made based on how symptoms have responded. Bleeding on continuous HRT that persists beyond 3 to 6 months is investigated; our article on bleeding on continuous HRT covers this.
- Ongoing review — usually annually. This covers symptom control, dose, and the benefit-risk balance over time.
Specialist referral is considered where the picture is complex: early menopause or premature ovarian insufficiency, a history of hormone-sensitive cancer, complex medical history, or symptoms that aren't responding to standard treatment. Specialist menopause clinics also help where testosterone is being considered for persistent low libido after other symptoms are controlled. You can browse our wider women's health writing in the Women's Health category.
Working with your Farmeci clinician
The most useful thing you can bring to a menopause consultation is a clear picture of what's actually happening: which symptoms bother you most, how they affect your day-to-day, when they started, how your periods have changed, and what — if anything — you've already tried. The clinician uses that to work out whether you're in perimenopause or menopause, what's likely to help, and whether HRT, a non-hormonal medicine, CBT, lifestyle changes, or a combination fits best. Menopause management is not one-and-done; expect a couple of reviews to find the right balance for you.